14 research outputs found
Interview with Marcelle C. Layton, MD Assistant Commissioner, Bureau of Communicable Disease New York City Department of Health and Mental Hygiene
No full textInterview with Donald F. Thompson, MD, MPH, TM Chief, Interagency and International Branch, North American Aerospace Defense Command— United States Northern Command Surgeon's Office
No full textInterview with Dennis S. O'Leary, MD, President, Joint Commission on Accreditation of Healthcare Organizations
No full textSecret agents : the manace of emerging infections
No full textThe most ceaselessly creative bioterrorist is still Mother Nature. And her microbial operatives are all around us, thriving in the shadows, ready to pounce when conditions are right. From airborne anthrax to West Nile virus, from the deadly organism hiding in our food to the next inevitable flu pandemic, Secret Agents reveals just what we`re up against in human-kind`s perpetual war with germs
John M. Barry, Distinguished Scholar at the Center for Bioenvironmental Research, Tulane and Xavier Universities, and Author of The Great Influenza
No full textInterview with Jean L. Patterson, PhD, Chairman, Department of Virology and Immunology, Southwest Foundation for Biomedical Research
No full textImplications of Overdiagnosis: Impact on Screening Mammography Practices
No full textThis review article explores the issue of overdiagnosis in screening mammography. Overdiagnosis is the screen detection of a breast cancer, histologically confirmed, that might not otherwise become clinically apparent during the lifetime of the patient. While screening mammography is an imperfect tool, it remains the best tool we have to diagnose breast cancer early, before a patient is symptomatic and at a time when chances of survival and options for treatment are most favorable. In 2015, an estimated 231,840 new cases of breast cancer (excluding ductal carcinoma in situ) will be diagnosed in the United States, and some 40,290 women will die. Despite these data, screening mammography for women ages 40-69 has contributed to a substantial reduction in breast cancer mortality, and organized screening programs have led to a shift from late-stage diagnosis to early-stage detection. Current estimates of overdiagnosis in screening mammography vary widely, from 0% to upwards of 30% of diagnosed cancers. This range reflects the fact that measuring overdiagnosis is not a straightforward calculation, but usually one based on different sets of assumptions and often biased by methodological flaws. The recent development of tomosynthesis, which creates high-resolution, three-dimensional images, has increased breast cancer detection while reducing false recalls. Because the greatest harm of overdiagnosis is overtreatment, the key goal should not be less diagnosis but better treatment decision tools. (Population Health Management 2015;18:S3-S11)
